HTR1A and major depressive disorder: Vilazodone (Fig. 1A), a 5 hydroxytryptamine receptor 1A (5-HT1A) partial agonist and selective reuptake inhibitor, has been approved by the FDA for the treatment of major depressive disorder in adults [12, 13].